Novartis sues Chinese firm over attempts to make generic heart failure drug
Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto (sacubitril/valsartan).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 July 2021 A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
18 June 2020 Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.